Form D · Biotechnology
Foresight Biotherapeutics, Inc.
New York, NY · CIK 0001526947
Offering snapshot reported Nov 13, 2013 · SEC filing
- Reported sold
- $15M Offering amount: $15M
- Investors reported
- 2 Form D · investor count
- Minimum accepted
- $15M Reported outside-investor minimum
- First sale
- Oct 30, 2013 As reported in this filing
What changed?
Latest filing versus its linked predecessor, where available.
No comparable changes in the displayed metrics.
Filing history
Scroll to see all columns →
| Filed | Filing type | Reported sold | Change vs linked filing | Investors | Source |
|---|---|---|---|---|---|
| Nov 13, 2013 | Initial | $15,000,000 | No comparison | 2 | SEC filing |
| Jul 29, 2011 | Initial | $2,000,290 | No comparison | 1 | SEC filing |
Offering details
- Securities
- Equity, Option to acquire, Security to be acquired
- Exemptions
- 06c
- Duration over one year
- No
- Business combination
- No
- Sales commissions
- $0
- Finders' fees
- $0
- Form D file number
- 021-206282
Source: Form D, filed Nov 13, 2013. Minimum accepted may differ from a standard advertised minimum.
Fund connections
No confirmed ADV fund connection is available for this issuer.
People & organizations
Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.
| Name | Reported role |
|---|---|
| Stephen Rocamboli | Director |
| Jason Stein | Director, Executive |
| Michael Weiser | Director, Executive |
Issuer details
Industry: Biotechnology (See others in industry)
Address:
50 West 57 Th Street 15 Th Floor
New York, NY, 10019
New York, NY, 10019